利用基因组调整辐射剂量(GARD)模型探索乳腺癌和前列腺癌RNA-seq衍生的放射敏感性
本研究利用公开RNA-seq数据,对1例Luminal B型乳腺癌患者和14例前列腺癌患者的肿瘤及邻近正常活检组织估算放射敏感性指数(RSI)与GARD值。乳腺癌患者肿瘤与正常组织的放射生物学属性差异明显,前列腺癌队列中差异较模糊;以前列腺癌队列肿瘤GARD中位值为阈值,提示半数患者可能从高于72 Gy/36fx的总剂量获益。
要点
- 乳腺癌患者肿瘤与邻近正常组织的放射生物学属性存在明显临床相关差异。
- 前列腺癌队列中肿瘤与正常组织间差异较模糊。
- 以前列腺癌肿瘤GARD中位值为高治疗效应阈值,半数患者可能从高于72 Gy/36fx的总剂量获益。
核心结论
- 本探索性研究显示,GARD模型结合测序转录组学可能有助于为乳腺癌和前列腺癌患者提供个体化放疗实践信息。
研究设计与样本
- 利用公开RNA-seq转录组数据,纳入1例Luminal B型乳腺癌患者和14例前列腺癌患者,对每例个体的肿瘤及邻近正常活检组织估算RSI和GARD值。
主要发现
- 乳腺癌患者肿瘤与邻近正常组织的衍生放射生物学属性存在明显临床相关差异。
- 前列腺癌队列中肿瘤与邻近正常组织间的此类差异较模糊。
- 以前列腺癌队列肿瘤预测GARD中位值为高治疗效应阈值,发现高于常用72 Gy/36fx的总处方剂量可能使半数患者获益。
关键数值与推荐
- 采用10基因转录特征作为GARD模型的一部分。
- 以前列腺癌队列肿瘤预测GARD中位值作为高治疗效应阈值。
- 常用总处方剂量为72 Gy/36fx。
临床怎么用
- 作者认为GARD模型结合测序转录组学可能为乳腺癌和前列腺癌患者的个体化放疗实践提供信息。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The use of a 10 gene transcriptional signature as part of the GARD model has been shown to be predictive of radiotherapy benefit for a range of cancers, with the potential to determine an optimal overall dose per patient. We used publicly available RNA-seq transcriptomics data from a luminal B breast cancer patient and from 14 prostate cancer patients to explore the radiosensitivity indices (RSI) and so GARD estimates of both tumour and proximal normal biopsies from each individual. Clear differences of clinical relevance in derived radiobiological properties between tumour and proximal normal tissues were evident for the breast cancer patient, whilst such differences across the prostate cancer cohort were more equivocal. Using the prostate cancer cohort's median tumour predicted GARD value as a threshold for high therapeutic effect for radiotherapy, we found evidence that a higher overall prescribed dose than the widely used 72 Gy/36fx could benefit half of these patients. This exploratory study demonstrates the potential combining the GARD model with sequencing based transcriptomics could have in informing personalised radiotherapeutic practise for both breast and prostate cancer patients.
引用
- Nolan B, O'Sullivan B, Golden A, et al. Exploring breast and prostate cancer RNA-seq derived radiosensitivity with the Genomic Adjusted Radiation Dose (GARD) model. Clin Transl Radiat Oncol. 2022. PMID: 36017133. doi:10.1016/j.ctro.2022.08.002
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。